Article
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.
Science (New York, N.Y.) - 20 Nov 2015
Vacchelli Erika, Ma Yuting, Baracco Elisa E, Sistigu Antonella, Enot David P, Pietrocola Federico, Yang Heng, Adjemian Sandy, Chaba Kariman, Semeraro Michaela, Signore Michele, De Ninno Adele, Lucarini Valeria, Peschiaroli Francesca, Businaro Luca, Gerardino Annamaria, Manic Gwenola, Ulas Thomas, Günther Patrick, Schultze Joachim L, Kepp Oliver, Stoll Gautier, Lefebvre Céline, Mulot Claire, Castoldi Francesca, Rusakiewicz Sylvie, Ladoire Sylvain, Apetoh Lionel, Bravo-San Pedro José Manuel, Lucattelli Monica, Delarasse Cécile, Boige Valérie, Ducreux Michel, Delaloge Suzette, Borg Christophe, André Fabrice, Schiavoni Giovanna, Vitale Ilio, Laurent-Puig Pierre, Mattei Fabrizio, Zitvogel Laurence, Kroemer Guido
Abstract excerpt
Antitumor immunity driven by intratumoral dendritic cells contributes to the efficacy of anthracycline-based chemotherapy in cancer. We identified a loss-of-function allele of the gene coding for formyl peptide receptor 1 (FPR1) that was associated with poor metastasis-free and overall survival in breast and colorectal cancer patients receiving adjuvant chemotherapy. The therapeutic effects of anthracyclines were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.